sb 216763 has been researched along with Fibrosarcoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Abe, K; Aiba, H; Aoki, Y; Araki, Y; Bolidong, D; Domoto, T; Hayashi, K; Higuchi, T; Igarashi, K; Inatani, H; Minamoto, T; Miwa, S; Takeuchi, A; Taniguchi, Y; Tsuchiya, H; Yamamoto, N; Yonezawa, H | 1 |
1 other study(ies) available for sb 216763 and Fibrosarcoma
Article | Year |
---|---|
Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
Topics: Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase 4; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Injections, Intraperitoneal; Maleimides; Mice; Phosphorylation; RNA Interference; Sarcoma, Synovial; Thiazoles; Up-Regulation; Urea; Xenograft Model Antitumor Assays | 2020 |